TREVENA, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-12-31: Form 8-K; Period of report 2020-12-31; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2020-11-02: Form 8-K; Period of report 2020-11-02; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2020-10-30: Form 8-K; Period of report 2020-10-30; Description 8.01 Other Events; Details 8.01.
- 2020-08-13: Form 8-K; Period of report 2020-08-12; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-12-31 | 8-K | 2020-12-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | tm2039198d3_8k.htm |
| 2020-11-02 | 8-K | 2020-11-02 | 7.01 Regulation FD Disclosure | 7.01 On November 2, 2020, Trevena, Inc. (the "Company") updated its website to include an updated corporate presentation deck. | tm2034744d1_8k.htm |
| 2020-10-30 | 8-K | 2020-10-30 | 8.01 Other Events | 8.01 On October 30, 2020, Trevena, Inc. (the “Company”) issued a press release announcing that oliceridine has been classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (the “DEA”). | tm2034620-1_8k.htm |
| 2020-08-13 | 8-K | 2020-08-12 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On August 12, 2020, the Company issued a press release announcing pricing of the Offering. | tm2027353-1_8k.htm |
| 2020-08-11 | 8-K | 2020-08-11 | 8.01 Other Events | 8.01 On August 11, 2020, Trevena, Inc. (the “Company”) issued a press release announcing its intention to offer and sell shares of its common stock in an underwritten public offering. | tm2027223d3_8k.htm |
| 2020-08-10 | 8-K | 2020-08-07 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 On August 10, 2020, Trevena, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved its lead drug candidate, OLINVYK (oliceridine) injection, that is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternate treatments are inadequate. 7.01 On August 10, 2020, the Company updated its website to include an updated corporate presentation deck. 8.01 The information contained in Item 2.02 is incorporated in its entirety into this Item 8.01. | tm2027070d1_8k.htm |
| 2020-06-02 | 8-K | 2020-06-01 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On June 2, 2020, Trevena, Inc. (the “Company”) updated its website to include an updated corporate presentation deck. 8.01 On June 2, 2020, the Company issued a press release announcing that it has entered into a collaboration with Imperial College London to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome (ARDS) in COVID-19 patients. | tm2021041d1_8k.htm |
| 2020-05-26 | 8-K | 2020-05-26 | 8.01 Other Events | 8.01 On May 26, 2020, Trevena, Inc. (the “Company”) received notice from Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market confirming that the Staff has determined that for the last 10 consecutive business days, from May 11 to May 22, 2020, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. | tm2020955-1_8k.htm |
| 2020-05-18 | 8-K | 2020-05-18 | 7.01 Regulation FD Disclosure | 7.01 On May 18, 2020, Trevena, Inc. (the “Company”) updated its website to include a new corporate presentation deck. | tm2020036-2_8k.htm |
| 2020-05-18 | 8-K | 2020-05-17 | 7.01 Regulation FD Disclosure | 7.01 In its May 15, 2020 issue, the journal Circulation published online an article titled: β-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19, Manglik A, Wingler LM, Rockman, HA, Lefkowitz, RJ. | tm2020036-1_8k.htm |
| 2020-05-15 | 8-K | 2020-05-13 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 In connection with the Annual Meeting, there were 97,863,990 shares outstanding as of the March 16, 2020 record date, of which 74,154,314 shares, or approximately 76%, were present or represented by proxy at the Annual Meeting. | tm2019833-1_8k.htm |
| 2020-05-07 | 8-K | 2020-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | tm2016270d2_8k.htm |
| 2020-04-20 | 8-K | 2020-04-17 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On April 17, 2020, Trevena, Inc. (the “Company”) received notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that the 180-day grace period to regain compliance with the Minimum Bid Price Requirement under applicable Nasdaq rules has been extended due to the global market impact caused by COVID-19. | tm2016270-1_8k.htm |
| 2020-03-26 | 8-K | 2020-03-26 | 8.01 Other Events | 8.01 On March 26, 2020, Trevena, Inc. (the “Company”) announced that due to the global COVID-19 pandemic, enrollment has been paused in the proof-of-concept clinical trials for TRV250 (treatment of acute migraine) and TRV734 (opioid use disorder). | tm2012526-2_8k.htm |
| 2020-03-13 | 8-K | 2020-03-12 | 2.02 Results of Operations and Financial Condition | 2.02 On March 12, 2020, Trevena, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2019. | tm2012526d1_8k.htm |
| 2020-03-05 | 8-K | 2020-03-04 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On March 5, 2020, Trevena, Inc. (the “Company”) issued a press release announcing an updated and extended cash runway, with a preliminarily estimate of cash, cash equivalents, and marketable securities of approximately $35.8 million as of December 31, 2019, which the Company believes will be sufficient to fund the Company’s operating expenses, debt service, and capital expenditure requirements into the first quarter of 2021. 7.01 In connection with its press release dated March 5, 2020, the Company announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmitted New Drug Application (NDA) for IV oliceridine, the Company’s lead investigational asset for the management of moderate-to-severe acute pain. | tm2011771d1_8k.htm |
| 2020-03-04 | 8-K | 2020-03-03 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On March 3, 2020, Trevena, Inc. (the “Company”) received approval from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) to transfer the listing of the Company’s common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market (the “Approval”). | tm2011648-1_8k.htm |
| 2020-02-14 | 8-K | 2020-02-13 | 7.01 Regulation FD Disclosure | 7.01 On February 13, 2020, Trevena, Inc. (the “Company”) issued a press release announcing the appointment of Scott Applebaum as Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs. | tm203621d3_8k.htm |
| 2020-02-10 | 8-K | 2020-02-07 | 8.01 Other Events | 8.01 On February 10, 2020, Trevena, Inc. (the “Company”) issued a press release announcing that it has resubmitted the New Drug Application for IV oliceridine to the U.S. Food and Drug Administration. | tm206970d1_8k.htm |